Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation. To overcome this problem, we analysed the me...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongde, Stokes, William, Chater, Emily, Roy, Rajat, de Bruin, Elza, Hu, Yili, Liu, Zhigang, Smit, Egbert F, Heynen, Guus JJE, Downward, Julian, Seckl, Michael J, Wang, Yulan, Tang, Huiru, Pardo, Olivier E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037574/
https://www.ncbi.nlm.nih.gov/pubmed/27721983
http://dx.doi.org/10.1038/celldisc.2016.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037574/
https://www.ncbi.nlm.nih.gov/pubmed/27721983
http://dx.doi.org/10.1038/celldisc.2016.31

Ejemplares similares